COVID-19

A COVID-19 test for every situation

From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs.

Today, we offer a comprehensive portfolio of SARS-CoV-2 testing solutions on the market, covering the needs of clinical and research customers, from manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to the detection of previous viral exposure.

During this unprecedented COVID-19 pandemic, data on novel SARS-CoV-2 variants with potentially increased transmissibility is rapidly developing. Confronting these new variants demands constant surveillance on diagnostic impact and accelerated development of innovative research technologies. Learn how our R&D and medical teams are working around the clock to empower your research and diagnostic labs.

Quick pivot enables lab to serve community during pandemic

Great Lakes Labs president and CEO Michelle Volk redirected her lab’s focus from forensics to clinical medicine in reaction to the COVID-19 pandemic to provide her community with rapid, accurate testing, and peace of mind.

Diagnostic testing for COVID-19

We have developed a comprehensive portfolio of COVID-19 diagnostic testing solutions including targeted and multiplex PCR detection and rapid antibody tests. We also supports several testing protocols by providing test components and mid- to high-throughput automation solutions.

COVID-19 research solutions

Pandemics require accelerated development of innovative technologies to provide rapid and effective responses. QIAGEN supports scientists seeking to better understand the SARS-CoV-2 virus with research tools. Our portfolio includes a full spectrum of our high-performance NGS solutions and integrated bioinformatics pipelines that collectively drive a greater understanding of the multiple facets of SARS-CoV-2 biology.

Latest news on QIAGEN’s COVID-19 efforts

At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19.

We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. Stay up-to-date with our latest developments here.